A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Inclusion Criteria: 1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form. 2. Male or female ≥ 18 years old and ≤75 years old. 3. ECOG performance status of 0-1. 4. With a life expectancy of ≥12 weeks. 5. With unresectable locally advanced or metastatic solid tumors harbouring with KRAS G12D mutation confirmed by central laboratory testing. 6. Need to provided tumor tissue samples for genetic testing. 7. Have at least one measurable lesion according to RECIST1.1, and the dose-escalation phase allows no measurable lesion. 8. Adequate laboratory parameters during the screening period. Exclusion Criteria: 1. Accompanied by untreated or active central nervous system (CNS) metastases. Subjects with a history or current history of meningeal metastasis. 2. Systemic antitumor therapy was received 4 weeks before the start of the study. 3. Palliative radiotherapy was completed within 14 days before the first dose. 4. Toxicity and/or complications from previous interventions did not return to NCI-CTCAE level ≤1 or exclusion criteria. 5. Subjects with known or suspected interstitial pneumonia. 6. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion. 7. Have poorly controlled or severe cardiovascular disease. 8. Subjects with active hepatitis B or active hepatitis C. 9. A history of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation. 10. The presence of uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse, and criminal detention. 11. Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.